TNFRSF17 and systemic lupus erythematosus: This autocrine loop could be of significant relevance to SLE pathogenesis and treatment, as highlighted by the therapeutic benefits of agents targeting components, such as TACI-Ig and anti-BCMA strategies, including BCMA CAR-T-cell therapy57.